期刊文献+

萘哌地尔在高血压患者体内的药动-药效学研究 被引量:3

Pharmacokinetics and pharmacodynamics of naftopidil in Chinese patients with hypertension
下载PDF
导出
摘要 目的:探索新型α-受体阻滞剂萘哌地尔在中国高血压病患者体内的药动学及降压效果。方法:10例高血压病患者单次口服萘哌地尔50 mg,用反相HPLC荧光检测方法测定患者血浆中萘哌地尔的浓度。用3P87程序软件处理数据;抽血测血药浓度的同时,亦进行动态血压监测,分析患者体内血药浓度与降压效应之间的关系。结果:单次口服萘哌地尔50 mg在中国高血压病患者体内符合一室模型、一级吸收过程;平均药动学参数分别为t_(1/2) 6.03 h,T_(max) 2.59 h,C_(max) 71.86 ng·mL^(-1),AUC 321.07 ng·h·mL^(-1),CL 195.5 L·h^(-1)。随着患者体内血药浓度的上升,血压有逐渐下降的趋势,同时伴心率增快,无心动过速和体位性低血压的现象发生。结论:萘哌地尔在中国高血压病患者体内的药动学特点与健康志愿者基本一致,适用于中国高血压患者的降压治疗。 Objective: To explore the pharmacokinetics and antihypertensive effect of nafiopidil, a novel selective α1-adrenoceptor antagonist .Methods: 10 essential hypertensive patients were administered a single oral dose of naftopidil 50 mg. The blood samples from the patients were collected to determine the plasma levels of naftopidil by RP-HPLC with fluorescence detection. A 24-hour ambulatory blood pressure monitoring was simultaneously performed. Results: The pharmacokinetic profile of naftopidil obeyed one-compartment model and first-order absorption with t1/2 6.03 h, T 2.59 h, C 71.86 ng· mL^-1 and AUC 321.07 ng·h·mL^-1. The blood pressure was gradually reduced in a positive plasma naftopidil-dependent manner. The patients experienced faster heartbeats and no tachycardia and orthostatic hypotension. Conclusion:Naftopidil offered a therapeutic option in Chinese patients with hypertension.
出处 《中国新药杂志》 CAS CSCD 北大核心 2006年第16期1397-1400,共4页 Chinese Journal of New Drugs
关键词 萘哌地尔 Α-受体阻滞剂 药动学 高血压 动态血压监测 naftopidil α1-adrenoceptor antagonist pharmacokinetics hypertension 24-hour ambulatory blood pressure monitoring
  • 引文网络
  • 相关文献

参考文献5

  • 1TAKEI R,IKEGAKI I,SHIBATA K,et al.Naftopidil,a novel alpha1-adrenoceptor antagonist,displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human alphaladrenoceptors[J].Jpn J Pharmacol,1999,79(4):447 -454.
  • 2ALARAYYED NA,PRICHARD BN,BETTERIDGE DJ,et al.Differential actionof naftopidil,doxazosin and nifidipine on platelet thromboxane generation and platelet-derived growth factor efflux in vitro[J].Platelets,2002,13 (5/6):267-271.
  • 3TAKAHASHI S,TAJIMA A,MATSUSHIMA H,et al.Clinical efficacy of an alpha-adrenoceptor blocker(naftopidil) on overactive bladder symptoms in patients with benign prostatic hyperplasia[J].Int J Urol,2006,13(1):15-20.
  • 4倪立,李金恒,余海诚,曹晓梅.萘哌地尔胶囊和片剂在中国健康男性志愿受试者的生物等效性比较[J].中国临床药理学与治疗学,2004,9(2):208-211. 被引量:2
  • 5李峰,卢家红,盛美萍,江文德.人血浆萘哌地尔浓度的高效液相色谱法测定[J].上海医科大学学报,1998,25(1):63-65. 被引量:7

二级参考文献4

共引文献7

同被引文献21

  • 1吴惠金.浅述抗高血压药物的合理应用[J].中国医药导报,2007,4(06S):124-125. 被引量:9
  • 2He J,Whehon PK.Epidemiology and prevention of hypertension[J].Med Clin North Am,1997,81(5):1077-1097.
  • 3Hammarston J,Hogstedt B.Hype nsulinaemia as a risk factor for developing benign prostatic hyperplasia[J].Euro Urol,2001,39 (2):151-158.
  • 4国家药典委员会.中国药典:二部[S].北京:中国医药科技出版社,2010:179-80.
  • 5杨明根,赵晓昆.α1受体阻滞剂治疗良性前列腺增生合并高血压研究进展[J].中华男科学杂志,2007,13(9):830-834. 被引量:18
  • 6Takei R, Ikegaki I, Shibata K, et al. Naftopidil, a novel alphal-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human alphal-adrenoceptors [J]. Jpn J Pharmacol, 1999, 79 (4) : 447-454.
  • 7Himmel HM, Glossmann H, Ravens U. Naftopidil, a new alpha-adrenoceptor blocking agent with calcium antagonistic properties: characterization of Ca2+ antagonistic effects [J]. J Cardiovasc Pharmacol, 1991, 17 (2):213-221.
  • 8Kyatanwar AU, Jadhav KR, Kadam VJ. Self micro- emulsifying drug delivery system (SMEDDS) : review [J]. J Pharm Res, 2010, 3 (1) : 75-83.
  • 9Singh AK, Chaurasiya A, Awasthi A, et al. Oral bioavailability enhancement of exemestane from self-microemulsifying drug delivery system (SMEDDS) [J]. AAPS PharmSciTech, 2009, 10(3): 906-916.
  • 10Gursoy RN, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilie drugs [J]. Biomed Pharmacother, 2004, 58 (3) : 173 - 182.

引证文献3

二级引证文献3

相关主题

;
使用帮助 返回顶部